Insights Into Chronic Lymphocytic Leukemia (CLL) Southeast

Perspectives of community physicians from the Southeast region of the United States on the management of newly diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL)

Southeast – July 8, 2020

Faculty Chair

Matthew Davids, MD

Dana Farber Cancer Institute, Boston, MA, US

Example Report

Start discovering the insights

View Report


  • Report providing the insights from a moderated roundtable discussion focusing on treatment of CLL
    Disease state and data presentations were developed in conjunction with Dr Matthew Davids from Dana Farber Cancer Institute
    Insights on the following CLL therapies were obtained:

    • acalabrutinib,  ibrutinib, zanubrutinib, obinutuzumab, rituximab, venetoclax, duvelisib, idelalisib, FCR, BR
  • Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion


  • The group of advisors comprised community oncologists from the southeast region of the United States
  • Community oncologists were invited from Alabama, Georgia, Florida, South Carolina, Tennessee, and Virginia

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.